Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
We have initiated coverage of Herantis Pharma, a drug development company focused on neurodegenerative diseases. In this interview analyst Antti Siltanen sheds light on what the company does, what its drug candidate HER-096 is all about, competing drug candidates and other pressing questions regarding the company.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Herantis is a drug development company focused on neurodegenerative diseases. Herantis currently has one candidate in the clinical Phase I, HER-096, which the company develops as a disease-modifying drug for Parkinson's disease.
For biotech funding as a whole, 2023 marked a recovery (+47% vs. 2022) after a dry spell caused by inflation and rising interest rates in recent years. This growth was mainly driven by valuable partnership deals signed in Q4'23. The share of other sources of funding was roughly on a par with the previous year. The IPO market continued to be quiet, both in terms of the number of IPOs and the amount of funding raised.